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Abstract The mitogen-stimulated protein kinase p70s6k/p85s6k
(S6K) plays an essential role in cell proliferation and growth,
with inhibitors of the S6K signalling pathway showing promise as
anti-tumour therapeutics. Here, we report that the bisindolylma-
leimide derivative Ro 31-6045, previously reported to be inactive
as a kinase inhibitor, inhibited S6K activity in vivo with an
IC50 = 8 WM. Structure/function analysis using mutant forms of
S6K indicates that Ro 31-6045 inhibition is independent of the
upstream activator mTOR. Ro 31-6045 will prove useful in
elucidating the complex activation mechanism of S6K and its
independence from mTOR will allow confirmation of functional
data obtained using the mTOR inhibitor rapamycin. 1 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The mitogen-stimulated protein kinase p70s6k/p85s6k (S6K)
is a key player in the regulation of cell growth and prolifer-
ation. There are two isoforms of S6K, p70 and p85, which are
generated from alternative translation start sites in the same
transcript. The p85s6k isoform is identical to p70s6k, except for
a 23 amino acid extension at the amino-terminus that specif-
ically targets it to the nucleus [1]. Both isoforms play essential
roles in cell growth [2,3] through the regulation of protein
synthesis. Multiple phosphorylation of the 40S ribosomal pro-
tein S6 by S6K results in a speci¢c increase of translation
e⁄ciency for the family of essential mRNAs containing an
oligopyrimidine tract at their transcriptional start site
(5PTOP mRNAs). This class of mRNAs encode many com-
ponents of the protein synthetic machinery, i.e. ribosomal
proteins, translation initiation and elongation factors associ-
ated with regulating general protein synthesis rates, and rep-
resent up to 20% of the total mRNA in the cell [4,5].
S6K is regulated by a complex mechanism involving multi-
ple phosphorylation reactions. It is hypothesised that an ini-
tial yet-to-be-de¢ned conformational change is required to
break an inhibitory interaction between the C- and N-termini
and thus allow phosphorylation at four sites within the C-ter-
minal autoinhibitory domain (S411, S418, S424 and T421).
This is followed by the sequential phosphorylation of T389
in a hydrophobic motif conserved in other AGC kinases and
¢nally the activating phosphorylation at T229 by the phos-
phoinositide-dependent kinase 1 (PDK1) [6,7]. Despite inten-
sive e¡ort, the signalling mechanisms responsible for the ini-
tial priming event and subsequent autoinhibitory domain
phosphorylation remain to be de¢ned. Recently the NimA-
related kinase, NEK6/7, has been implicated in the phosphor-
ylation of T389 but a physiological role in the activation of
S6K is yet to be proven [8].
Much of our understanding of this activation process stems
from the use of inhibitors of S6K signalling. Rapamycin and
its analogues inhibit the translational regulator mTOR that
acts as a bifurcation point to two pathways. mTOR is re-
quired for activation of S6K and also phosphorylates eIF-
4E-binding protein (4EBP-1), releasing its inhibitory interac-
tion with eIF-4E to increase global translation rates [9]. The
mechanism by which mTOR regulates S6K remains to be
elucidated but its inhibition by rapamycin abolishes phos-
phorylation of the critical residues T389 and T229 [10]. Acti-
vation of S6K is also phosphatidylinositol 3-kinase (PI3K)-
dependent with the PI3K inhibitor wortmannin potently in-
hibiting S6K [11] and this dependence is apparently mediated
via PDK1 phosphorylating T229 [12]. Mutation of T389 to a
glutamic acid residue renders the kinase rapamycin and wort-
mannin resistant [10,13], indicating that the two pathways
converge to regulate T389 phosphorylation. Importantly how-
ever, deletion analysis of the N- and C-termini resulted in a
mutant kinase that remains dependent on PI3K activity (wort-
mannin-sensitive) but is independent of mTOR (rapamycin
resistant) [13]. This observation supports the existence of an
additional input necessary for activation of the kinase.
Selective inhibitors of protein kinases have been used to
provide insight into both the mode of regulation and physio-
logical roles of the targeted enzymes. Extensive screening of
these compounds has revealed most have overlapping specif-
icities, complicating interpretation of their e¡ects on cell sys-
tems [14]. Rapamycin is one of the most selective but has still
been implicated in the regulation of multiple pathways for
example by altering the levels of cyclin D and the cdk inhib-
itor protein p27Kip1 in addition to its e¡ects on mTOR, S6K
and 4EBP-1 [15]. In this study searching for alternative inhib-
itors of S6K we found that the bisindolylmaleimide derivative
Ro 31-6045, previously reported to be inactive as a kinase
inhibitor [16], inhibited endogenous S6K activity in stimulated
¢broblasts. Structure/function analysis using S6K mutants re-
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vealed Ro 31-6045 blocked activation of the kinase by inhib-
iting phosphorylation of T389 independently of mTOR and
led us to propose that the inhibitor may target a novel acti-
vation pathway. Ro 31-6045 will prove useful in elucidating
the complex activation mechanism of S6K and its indepen-
dence from mTOR will allow con¢rmation of functional data
obtained using the mTOR inhibitor rapamycin. Furthermore,
Ro 31-6045 may provide the basis for the development of
speci¢c inhibitors of S6K of potential therapeutic importance.
2. Materials and methods
2.1. Materials
Ro 31-8220 and Ro 31-6045 were purchased from Alexis Corpora-
tion, UK. H89 and H85 were purchased from Seikagaku, USA.
Extracellular growth factor (EGF) was purchased from Auspep, Aus-
tralia, serum and tissue culture media from Gibco BRL, and general
chemicals from Sigma.
2.2. Cell culture and preparation of cell extracts
HEK293 and Balb/c 3T3 cells were maintained in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) supplemented with 10% foetal calf
serum at 37‡C in a 5% CO2 atmosphere. Balb/c 3T3 cells were plated
at 2U106 per 10 cm plate for 24 h, then made quiescent by culturing
for 24 h, in DMEM containing no serum. Serum-starved cells were
rinsed twice with HEPES bu¡er solution containing 120 mM NaCl
and 20 mM HEPES, pH 7.4. Cells were then treated at 37‡C with
5 nM EGF for 5 min. Alternatively, the cells were pretreated for
20 min with varying concentrations of Ro 31-8220, H89, Ro 31-
6045 or H85 as indicated. Following stimulation, the cells were rinsed
twice with ice cold phosphate-bu¡ered saline (PBS) and lysed in a
bu¡er containing 50 mM Tris, pH 7.5, 120 mM NaCl, 1% Nonidet-
P40, 1 mM EDTA, 50 mM NaF, 40 mM L-glycerophosphate, 0.1 mM
sodium vanadate, 1 mM benzamidine, 0.5 mM phenylmethylsulfonyl
£uoride. Cell extracts were collected with a plastic scraper, and
cleared by centrifugation at 4‡C for 15 min at 12 000Ug. Protein
concentration was measured by the method of Bradford (Bio-Rad),
with bovine serum albumin as standard. Aliquots of the supernatant
were frozen in liquid nitrogen and stored at 370‡C.
2.3. Transient transfections
HEK293 cells were plated at 1U106 per 10 cm plate and 24 h after
plating were transfected with p70s6k expression constructs tagged with
the myc epitope using the calcium phosphate method as described
previously [17] or with myc epitope-tagged PDK1 [18]. The constructs
used were wild-type (2B4); constitutively active, rapamycin and wort-
mannin resistant (dED3E) with T389 and T421 mutated to glutamic
acid and S411, S418, and S424 mutated to aspartic acid residues; the
rapamycin resistant, wortmannin-sensitive double truncation mutant
(vNvC) missing residues 1^54 and 389^502 and vNvC with T389
mutated to glutamic acid (vNvC389E). Twenty-four hours after
transfection, the cells were serum-starved for 24 h. Following se-
rum-starvation the cells were rinsed with HEPES bu¡er and stimu-
lated with 20% serum for 20 min. Alternatively the cells were pre-
treated with varying concentrations of Ro 31-8220, Ro 31-6045, H89
or H85 as indicated. Following stimulation the cells were washed and
harvested as above.
2.4. S6K, Akt and PDK1 activity assays
Endogenous S6K activity was assayed as described previously [19]
using 40S ribosomes as substrate. Myc-tagged p70s6k was immunopre-
cipitated and assayed as described previously [10]. Akt activity was
assayed as described previously using RPRAATF peptide as substrate
[20]. The results are expressed in units of activity per mg protein lysate
or as % of control values. One unit of activity results in the transfer of
1 pmol of 32Pi to the respective substrate per minute. Autophosphor-
ylation activity of myc-tagged PDK1 was determined essentially as
reported previously [21]. Brie£y, myc-PDK1 was immunoprecipitated
from 250 Wg of extracts from transiently transfected HEK293 cells and
the washed immunocomplexes incubated for 20 min at 30‡C in a total
volume of 20 Wl of 25 mM Tris^HCl pH 7.5, 0.5 mM dithiothreitol,
0.5 mM benzamidine, 50 WM [Q-32P]ATP (5000 cpm/pmol) and 10 mM
MgCl2. The reaction was stopped by boiling in SDS^polyacrylamide
gel electrophoresis (SDS^PAGE) sample bu¡er and proteins resolved
by SDS^PAGE. Phosphorylation of PDK1 was visualised by auto-
radiography of the dried gel and quantitated by liquid scintillation
counting of excised bands.
2.5. Western blotting
Whole protein extracts (50 Wg) were subjected to SDS^PAGE on
15% gel slabs with 5% stacking gels at 200 V for 1 h. Proteins were
transferred onto Immobilon-P PVDF membrane (Millipore) using the
Trans-Blot Semi-Dry Electrophoretic Transfer Cell (Bio-Rad) at 12 V
(V100 mA) for 30 min. Following transfer, the membrane was
blocked for 30 min in PBS containing 5% (w/v) skim milk powder
and 0.5% (v/v) Tween-20 (PBSM). The membrane was incubated at
room temperature for 1 h with either the phospho-4EBP-1 (Cell Sig-
nalling #9451), actin (ICN #691001), phospho-T389 (Cell Signalling
#9205F) or 9E10 anti-myc tag antibodies diluted 1:1000 in PBSM.
After washing the blot was incubated with horseradish peroxidase
anti-rabbit or anti-mouse secondary antibodies diluted 1:2000 at
room temperature for 1 h, the immunoblot complex visualised by
the enhanced chemiluminescence method (NEN Life Science) and
detected by exposure to X-ray ¢lm (Kodak).
3. Results
3.1. E¡ects of Ro 31-8220, H89, Ro 31-6045 and H85 on
in vivo activation of S6K
In order to search for selective inhibitors of S6K signalling
we have investigated the in vivo potency of two commonly
used inhibitors of AGC family kinases, the protein kinase C
(PKC) inhibitor Ro 31-8220 and the protein kinase A (PKA)
inhibitor H89 that have been shown to inhibit S6K in vitro
[14,22]. Their inactive analogues Ro 31-6045 [16] and H85
were incorporated as speci¢city controls (Fig. 1). Ro 31-
8220 and H89 potently inhibited EGF-induced activation of
S6K in ¢broblasts with IC50 values of 600 nM and 3 WM
respectively. Surprisingly, Ro 31-6045 also inhibited S6K
with IC50 = 8 WM and H85 with IC50 = 25 WM. None of these
Fig. 1. E¡ects of Ro 31-8820, H89, Ro 31-6045 and H85 on in vivo
activation of S6K. Balb/c 3T3 cells were plated, serum-starved for
24 h, pretreated with varying concentrations of Ro 31-8220, H89,
Ro 31-6045 and H85 as indicated for 20 min, then stimulated with
EGF (5 nM) for 5 min and harvested. S6 kinase assay was per-
formed as described under Section 2, normalised to control (EGF-
stimulated) and graphed (meanSS.E.M.) with increasing concentra-
tions of drug. The IC50 values are: Ro 31-8220 ^ 6U1037 M, H89
^ 3U1036 M, Ro 31-6045 ^ 8U1036 M and H85 ^ 2.5U1035 M.
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compounds inhibited the related kinase Akt at 5 WM, a con-
centration that signi¢cantly inhibited S6K activation (Fig.
2A,B). Interestingly, both Ro 31-8220 and H89 reproducibly
enhanced Akt activity.
3.2. E¡ects of Ro 31-8820, H89, Ro 31-6045 and H85 on
in vitro activity of S6K
Both the bisindolylmaleimide (Ro 31-8220 and Ro 31-6045)
and isoquinolinesulfonamide analogues (H89 and H85) were
designed to compete with ATP for binding to the active site of
kinases. In order to determine whether all the inhibitors di-
rectly a¡ected S6K activity, epitope-tagged wild-type S6K was
expressed in serum-stimulated HEK293 cells, immuno-puri¢ed
and assayed for activity at varying doses of each inhibitor
(Fig. 3). While Ro 31-8220, H89 and H85 all inhibited S6K
in vitro, Ro 31-6045 had no e¡ect up to 100 WM, indicating
this compound may be acting via inhibition of an upstream
signalling pathway.
3.3. E¡ects of Ro 31-6045 on PDK1 signalling
PDK1-catalysed phosphorylation of T229 in the activation
loop of S6K is the best characterised activating mechanism for
the kinase. PDK1 also activates other AGC kinase family
members including Akt, PKA and PKC via phosphorylation
of homologous residues [23]. While PKA and PKC have been
Fig. 2. E¡ects of Ro 31-8820, H89, Ro 31-6045 and H85 on in vivo
activation of S6K and Akt activity. Balb/c 3T3 cells were plated,
serum-starved for 24 h, pretreated with 5U1036 M Ro 31-8820,
H89, Ro 31-6045 or H85 for 20 min, then stimulated with EGF for
5 min and harvested. S6K and Akt assays were performed as de-
scribed under Section 2. The data shown are the meanSS.E.M. of
the Akt and S6K activity in pmol Pi/mg protein/min.
Fig. 3. E¡ects of Ro 31-8820, H89, Ro 31-6045 and H85 on in vitro
activation of S6K. HEK293 cells were plated, transfected with wild-
type myc-tagged S6K for 24 h before being serum-starved for 24 h,
then stimulated with serum for 20 min and harvested. Myc-tagged
S6K was immunoprecipitated and the precipitated kinase incubated
with increasing doses of each inhibitor as indicated for 20 min then
assayed as described under Section 2. The results were normalised
to control (serum-starved) and graphed (meanSS.E.M.) with in-
creasing concentrations of drug. The IC50 values are: Ro 31-8220 ^
3U1037 M, H89 ^ 5U1037 M and H85 ^ 1.5U1036 M.
Fig. 4. E¡ects of Ro 31-6045 on PDK1 signalling. A: Balb/c 3T3
cells were plated, serum-starved for 24 h, pretreated with varying
concentrations of Ro 31-6045 as indicated for 20 min, then stimu-
lated with EGF (5 nM) for 5 min and harvested. S6 kinase and Akt
assays were performed as described under Section 2, normalised to
control (EGF-stimulated) and graphed (meanSS.E.M.) with increas-
ing concentrations of drug. B: HEK293 cells were plated, trans-
fected with myc-tagged PDK1 for 24 h and then serum-starved for
24 h, pretreated with varying concentrations of Ro 31-6045 as indi-
cated for 20 min, then stimulated with serum for 20 min and har-
vested. Myc-tagged S6K was immunoprecipitated and assayed for
autophosphorylation activity as described under Section 2.
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shown to be resistant to Ro 31-6045 up to 100 WM [16], it is
theoretically possible that Ro 31-6045 inhibits PDK1 and the
resistant kinases require lower levels of PDK1 activity. In
order to test this possibility, a detailed dose^response curve
of the e¡ects of Ro 31-6045 on Akt, the kinase most closely
related to S6K, was carried out (Fig. 4A). Akt was weakly
inhibited with an IC50s 50 WM, 10-fold higher than for S6K.
Furthermore, Ro 31-6045 had no e¡ect on the activity of
PDK1 exogenously expressed in HEK293 cells at concentra-
tions up to 100 WM (Fig. 4B), consistent with the resistance of
PKA and PKC and indicating that Ro 31-6045 does not act
via PDK1.
3.4. E¡ects of Ro 31-6045 on in vivo activation of S6K mutants
In order to further delineate the mechanism of action of Ro
31-6045 we determined the e¡ect of this inhibitor on the ac-
tivity of some S6K structure/function mutants. S6K is acti-
vated by a complex mechanism involving wortmannin-sensi-
tive activation of PI3K and signalling via the rapamycin-
sensitive kinase mTOR. A mutant form of S6K with the hy-
drophobic motif phosphorylation site and three autoinhibi-
tory sites substituted with acidic residues (dED3E) is resistant
to inactivation by both wortmannin and rapamycin [10,13].
Deleting portions of the C- and N-termini of the kinase results
in a mutant (vNvC) that remains resistant to rapamycin but
sensitive to wortmannin [13], indicating a clear di¡erence be-
tween the two processes. As both mutants are phosphorylated
on T229, the target site of the PI3K-dependent activator
PDK1, it is likely that this double deletion mutant reveals a
novel signalling pathway [24]. Because these mutants appar-
ently distinguish the two activating pathways, each was tested
for its sensitivity to inhibition by Ro 31-6045 (Fig. 5A). Like
wortmannin, Ro 31-6045 failed to signi¢cantly inhibit the ac-
tivity of the constitutively active dED3E mutant at concen-
trations that reduced the activity of both the double trunca-
tion mutant and wild-type enzyme by 80%. Western blot
analysis of these extracts using the phospho-T389 antibody
revealed that the inhibition of wild-type and vNvC by Ro
31-6045 was accompanied by the reduction of Thr-389 phos-
phorylation to levels similar to baseline (Fig. 5B), consistent
with the inhibitor targeting phosphorylation of this key regu-
latory site. Indeed, substitution of T389 with glutamic acid
renders vNvC totally resistant to Ro 31-6045 (Fig. 5A), con-
¢rming T389 phosphorylation as the critical target for inhibi-
tion.
4. Discussion
In the present study we have shown that two commonly
used inhibitors of AGC family kinases, the PKC inhibitor
Ro 31-8220 and the PKA inhibitor H89, also inhibit S6K in
vivo, consistent with previous reports that they inhibited S6K
in vitro [14,22]. Surprisingly, their inactive analogues Ro 31-
6045 and H85 also inhibited EGF-induced activation of S6K
in ¢broblasts. In fact, the 8 WM IC50 determined for Ro 31-
6045 is comparable to that of H89 (3 WM) and consistent with
the low micromolar IC50 values reported for other kinases in
cell-based assays [14]. These observations reinforce the need
for careful controls in interpreting the results of inhibitor
studies in cell-based assays. Clearly, even the use of inactive
analogues can be complicated by altered inhibitor speci¢city.
The gold standard for these studies will be the ability of drug
resistant forms of the kinase to reverse the e¡ects of the in-
hibitor. It is perhaps not surprising that H85 shows some
inhibitory activity as although it does not inhibit PKA, it
does target other kinases including Ca2þ/CaM kinase II,
MLCK and casein kinase 1 [25]. On the other hand Ro 31-
6045 had no e¡ect on PKC, PKA or Ca2þ/CaM kinase II even
at 100 WM [16].
Unlike the other three compounds, Ro 31-6045 did not
inhibit S6K in vitro, implying it targeted an upstream activa-
tion pathway. Analysis of its e¡ects on the mutant forms of
the kinase revealed the inhibition was associated with dephos-
phorylation of T389. Thus Ro 31-6045 apparently targets a
T389 kinase but this is independent of mTOR signalling as the
rapamycin resistant mutant vNvC is sensitive to Ro 31-6045.
As the utility of this inhibitor to assess S6K signalling inde-
pendent of rapamycin is a key ¢nding of this study, we used a
Fig. 5. E¡ects of Ro 31-6045 on in vivo activation of S6K mutants.
HEK293 cells were plated, transfected with wild-type, dED3E,
vNvC and vNvC389E myc-tagged S6K for 48 h before being se-
rum-starved for 24 h. The cells were then pretreated with varying
concentrations of Ro 31-6045 as indicated for 20 min then stimu-
lated with serum for 20 min and harvested. A: Myc-tagged S6K
was immunoprecipitated and assayed as described under Section 2.
The results were normalised to control (serum-starved) and graphed
(meanSS.E.M.) with increasing concentrations of drug. The IC50
for wild-type S6K was 8.5U1035 M and 5U1035 M for vNvC. B:
Cells expressing wild-type S6K (lanes 1^3) or vNvC (lanes 4^6)
were serum-starved (Ctl), serum-stimulated (Ser) or treated with 100
WM Ro 31-6045 (Ro) as described above, extracted and subjected to
Western blot analysis for S6K phosphorylated on T389, or for S6K
expression using the 9E10 K-myc tag monoclonal antibody as de-
scribed under Section 2.
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phospho-speci¢c antibody to the alternative mTOR substrate
4EBP-1 to con¢rm Ro 31-6045 did not a¡ect mTOR-catalysed
phosphorylation of 4EBP-1 up to 100 WM (Fig. 6).
This inhibition is not mediated via PDK1 as Ro 31-6045
does not inhibit the kinase at concentrations up to 100 WM,
consistent with the resistance of PKA and PKC reported pre-
viously [16]. Furthermore, Ro 31-6045 does not inhibit
dED3E, despite this mutant requiring T229 phosphorylation
by PDK1 for activity. It is likely that the weak e¡ect of the
inhibitor on Akt activity is mediated via the regulatory mech-
anism targeting S473, the carboxy-terminal hydrophobic
phosphorylation site highly homologous to T389 in S6K.
Ro 31-6045 thus provides a new tool for examining the
mechanism of activation and signalling of S6K. In particular,
it will be important to assess the e¡ects of Ro 31-6045 on the
newly discovered potential T389 kinase NEK6/7 and the in-
hibitor may provide a useful tool for probing the physiolog-
ical role of this enzyme in activating S6K. Given Ro 31-6045
is a bisindoylmaleimide analogue of staurosporine it is likely
to be acting as a competitive inhibitor of ATP-binding and
thus may be a suitable compound for a⁄nity purifying the
putative mTOR-independent T389 kinase. The utility of this
approach was initially shown for ATP itself coupled to an
agarose support [26].
The observation that overexpression of wild-type S6K in
HEK293 cells increases the IC50 10-fold from that of endog-
enous S6K in ¢broblasts raises the possibility that Ro 31-6045
also targets the inactive form of the kinase, as reported for the
inhibition of MKK1 by U0126 and PD 184352 [14] and SAP-
K2a by SB 203580 [27]. Alternatively, this di¡erence may
re£ect inherent di¡erences of drug sensitivity of each cell
line, or perhaps is due to the variety of growth factors used.
Nonetheless, Ro 31-6045 provides the facility for probing S6K
function independent of rapamycin inhibition of mTOR in
cell-based experiments. Although rapamycin is one of the
most selective signalling inhibitors reported [14] it has still
been implicated in the regulation of multiple pathways. The
availability of an Ro 31-6045-independent mutant of S6K will
allow convenient validation of the implied roles of the kinase
in the control of a cellular process.
In addition to aiding in the analysis of S6K signalling, Ro
31-6045 may provide a lead compound for development of
S6K signalling-speci¢c inhibitors of therapeutic importance.
Maintenance of a sustained elevated rate of protein synthesis
is a fundamental requirement for tumour formation. Over the
last year analogues of the S6K signalling pathway antagonist,
rapamycin have been tested in pre-clinical and phase I studies
with preliminary evidence of anti-tumour e¡ects being ob-
served in renal cell carcinoma and non-small cell lung cancer
[28]. In fact, a speci¢c role for S6K in breast cancer has been
inferred from the observation that the S6K gene is ampli¢ed
and the protein overexpressed in a number of breast cancer
cell lines and 8% (68/698) of primary tumours [29].
In summary, we have identi¢ed the bisindolylmaleimide de-
rivative Ro 31-6045 as an in vivo inhibitor of S6K. Structure/
function analysis using mutant forms of S6K indicates that
Ro 31-6045 targets T389 phosphorylation independent of the
upstream activator mTOR. This inhibitor will prove useful in
elucidating the complex activation mechanism of S6K, and in
combination with a drug resistant mutant of S6K (dED3E),
this reagent will allow rapamycin-independent analysis of S6K
signalling in cell-based systems. In addition, Ro 31-6045 may
provide a lead in the development of S6K-speci¢c inhibitors
of tumour growth.
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4EBP-1, or actin as a loading control as described under Section 2.
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